Meet our Board of Directors
President and Chief Executive Officer
Guido Baechler was appointed President and Chief Executive Officer of Singulex in May 2013. Mr. Baechler has worked with emerging technologies in the life sciences and the diagnostics industries for more than two decades, including serving in leadership positions at Roche, and, since 2010, as Senior Vice President of Operations at Singulex. Prior to 2010, Mr. Baechler served as Singulex’s Vice President of Diagnostics from 2008 until 2009. From 1989 until 2008, Mr. Baechler held leadership positions at Roche Diagnostics and Roche Molecular Diagnostics, or RMD, in both Switzerland and the United States, within research, development, marketing and executive management. Mr. Baechler holds a bachelor’s degree in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He also completed a series of executive finance and management classes at the London School of Business and at the Haas Business School in Berkeley.
Heiner Dreismann, Ph.D.
Heiner Dreismann, Ph.D. has been a member of our board of directors since June of 2007 and has over 26 years of experience in biotech and healthcare companies. Since May of 2008, Dr. Dreismann has served as Interim Chief Executive Officer of GeneNews Limited, a public diagnostics company. From 2001 until 2006, Dr. Dreismann served as President and Chief Executive Officer of Roche Molecular Systems, Inc., a division of Hoffmann-La Roche Ltd., or Roche, focused on clinical molecular diagnostics. Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.
Carl L. Gordon, Ph.D., CFA
General Partner of OrbiMed and Co-Head of Private Equity
Carl Gordon, Ph.D., CFA has been a member of our board of directors since June of 2007. Dr. Gordon co-founded OrbiMed Advisors LLC, or OrbiMed, where he serves as a General Partner and Co-Head of Private Equity. He is experienced in both private equity and small-capitalization public equity investments. Prior to his experience at OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, a pharmaceutical consulting firm and predecessor to OrbiMed, from 1995 to 1997. From 1993 to 1995, Dr. Gordon was a fellow at The Rockefeller University. He received his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a bachelor’s degree from Harvard College. From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.
André Marion has been a member of our board of directors since June of 2006. Dr. Marion is an experienced entrepreneur and industry expert with over 25 years of management and commercialization experience in the life sciences industry. Dr. Marion was a founder of Applied Biosystems, Inc., or ABI, a large supplier of instruments for the biotechnology research market, where he worked from 1981 until 1995. He served as President, Chief Executive Officer and Chairman of the board of directors from 1987 through the time of ABI’s merger with Perkin Elmer Corporation in 1993. Prior to founding ABI, Dr. Marion held several research and development managerial positions at Hewlett-Packard Corporation. Dr. Marion holds an advanced degree from the French École Nationale Supérieure d’Arts et Métiers in both Mechanical and Electrical Engineering. With decades of experience in the life science sector, Dr. Marion provides our board of directors with seasoned business judgment and valuable insights relevant to our industry.
R. Douglas Norby
Doug Norby has been a member of our board of directors since July of 2012. Mr. Norby acquired more than 25 years of experience working as a financial executive in a range of industries for both early-stage and public companies before he retired from full-time employment in 2006. From 2003 until 2006, Mr. Norby served as the Senior Vice President and Chief Financial Officer for Tessera Technologies, Inc., a public semiconductor intellectual property company. Prior to his experience at Tessera, from 2000 to 2003, Mr. Norby served as the Chief Financial Officer for Zambeel, Inc., a data storage company, and Novalux, Inc., a manufacturer of lasers for optical networks. Prior to holding these positions, from 1996 to 2000, Mr. Norby served as the Senior Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company, where he also served as a director. From 1993 to 1996, Mr. Norby served as the Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company. Mr. Norby served as President of Pharmetrix Corporation, a drug delivery company, from 1992 to 1993, and from 1985 to 1992, he was President and Chief Operating Officer of Lucasfilm, Ltd., an entertainment company. Prior to this experience, from 1979 to 1985, Mr. Norby was Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company. Mr. Norby is currently a director of several semiconductor companies including Ikanos Communications, Inc., InvenSense, Inc., MagnaChip Semiconductor Corp and STATS ChipPAC, Ltd. He is also currently a director of Alexion Pharmaceuticals, Inc., a pharmaceutical company, and was a director of Intellon Corporation, a semiconductor company, from 2007 to 2009. Mr. Norby received a bachelor’s degree in Economics from Harvard University and an M.B.A. from Harvard Business School. Mr. Norby brings to our board of directors extensive experience related to business and financial issues as well as financial credentials and expertise conducive to his service on our audit committee.
Stephen L. Rose, CMA
Director, Fisk Ventures, LLC
Steve Rose, CMA has been a member of our board of directors since September of 2004. Mr. Rose serves as Managing Director of Fisk Ventures, LLC, or Fisk, which is the venture investment company for H. Fisk Johnson, Ph.D., Chairman of the Board, the Chairman and Chief Executive Officer of S.C. Johnson and Son Inc., or S.C. Johnson. In this capacity, Mr. Rose serves on the boards of several early-stage, technology-based companies and has over 15 years of experience in venture investing. Mr. Rose previously held several positions with S.C. Johnson, both in the United States and in Canada, including positions in strategic planning, new business and new product development, and financial and business management. Mr. Rose has an Honors Bachelor of Commerce from McMaster University and is also a Certified Management Accountant. As a venture capitalist with experience on several emerging company boards, Mr. Rose provides our board of directors with financial and operational expertise. In addition, his financial credentials and experience are valuable toward his service on our audit committee.
Fred K. Vogt
President of FKV Enterprises, LLC
Fred Vogt has been a member of our board of directors since our incorporation in 2002. Mr. Vogt has 28 years of operations and manufacturing experience in the pharmaceutical industry, and he currently provides consulting services to senior management executives through FKV Enterprises LLC. From 1997 until 2000, Mr. Vogt served as a Senior Vice President of Specialty Chemicals at Tetra Technologies Inc., a chemical manufacturer. Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.